Evidence map›Paper›PMID 38132156›Full record

ArticleCells2023

A Novel Approach: Investigating the Intracellular Clearance Mechanism of Glyceraldehyde-Derived Advanced Glycation End-Products Using the Artificial Checkpoint Kinase 1 d270KD Mutant as a Substrate Model.

Kenji Takeda, Akiko Sakai-Sakasai, Kouji Kajinami, Masayoshi Takeuchi

Open access · goldAbstract read
In one paragraph

Article in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Potential of Orally Administered Quercetin, Hesperidin, andInternational journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
  5. Article
  6. Toxic AGEs (TAGE) Cause Lifestyle-Related Diseases.Antioxidants (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kenji TakedaDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada-Machi, Ishikawa 920-0293, Japan.ORCID 0009-0004-0690-127X
Akiko Sakai-SakasaiDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada-Machi, Ishikawa 920-0293, Japan.ORCID 0000-0002-1258-1725
Kouji KajinamiDepartment of Cardiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada-Machi, Ishikawa 920-0293, Japan.ORCID 0000-0002-6013-2027
Masayoshi TakeuchiDepartment of Advanced Medicine, Medical Research Institute, Kanazawa Medical University, 1-1 Daigaku, Uchinada-Machi, Ishikawa 920-0293, Japan.ORCID 0000-0002-1057-3764
Kanazawa Medical University · JP

Funding

Japan Society for the Promotion of Science 20K08410Japan Society for the Promotion of Science 21H04865
6 · The paper itself

Abstract

Advanced glycation end-products (AGEs), formed through glyceraldehyde (GA) as an intermediate in non-enzymatic reactions with intracellular proteins, are cytotoxic and have been implicated in the pathogenesis of various diseases. Despite their significance, the mechanisms underlying the degradation of GA-derived AGEs (GA-AGEs) remain unclear. In the present study, we found that N-terminal checkpoint kinase 1 cleavage products (CHK1-CPs) and their mimic protein, d270WT, were degraded intracellularly post-GA exposure. Notably, a kinase-dead d270WT variant (d270KD) underwent rapid GA-induced degradation, primarily via the ubiquitin-proteasome pathway. The high-molecular-weight complexes formed by the GA stimulation of d270KD were abundant in the RIPA-insoluble fraction, which also contained high levels of GA-AGEs. Immunoprecipitation experiments indicated that the high-molecular-weight complexes of d270KD were modified by GA-AGEs and that p62/SQSTM1 was one of its components. The knockdown of p62 or treatment with chloroquine reduced the amount of high-molecular-weight complexes in the RIPA-insoluble fraction, indicating its involvement in the formation of GA-AGE aggregates. The present results suggest that the ubiquitin-proteasome pathway and p62 play a role in the degradation and aggregation of intracellular GA-AGEs. This study provides novel insights into the mechanisms underlying GA-AGE metabolism and may lead to the development of novel therapeutic strategies for diseases associated with the accumulation of GA-AGEs.

Indexed as

Glycation End Products, AdvancedGlyceraldehydeCheckpoint Kinase 1Maillard ReactionProteasome Endopeptidase ComplexUbiquitinsCheckpoint Kinase 1Glycation End Products, AdvancedGlyceraldehydeProteasome Endopeptidase ComplexUbiquitinsadvanced glycation end-products (AGEs)CHK1-CPsglyceraldehyde-derived AGEsglyceraldehyde (GA)p62/SQSTM1toxic AGEs (TAGEs)

Identifiers

PMID38132156
PMCPMC10741459
OpenAlexW4389794374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.